NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $25.07 0.00 (0.00%) Closing price 09/4/2026 04:00 PM EasternExtended Trading$24.87 -0.20 (-0.79%) As of 06:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$24.47▼$25.1450-Day Range$15.38▼$28.0152-Week Range$14.19▼$36.65Volume4.71 million shsAverage Volume5.30 million shsMarket Capitalization$7.08 billionP/E Ratio69.64Dividend YieldN/APrice Target$26.33Consensus RatingModerate Buy Company Overview Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology. Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis. In addition to clinical testing for patient care, the company offers translational science and clinical trial support services to biopharmaceutical partners, including biomarker discovery, assay development and companion diagnostic collaborations to facilitate drug development programs. The company primarily serves healthcare providers, cancer centers and biopharma customers in the United States and through international collaborations. Its offerings are used across the oncology care continuum—from initial profiling to inform therapy selection through longitudinal monitoring and research applications—positioning the business at the intersection of clinical diagnostics and precision oncology research. Caris emphasizes the integration of multi‑omic data and computational analysis to generate clinically actionable insights, and it engages with clinicians, researchers and industry partners to expand the use of molecular profiling in personalized cancer care. Detailed information about its leadership and corporate history is available through the company’s public filings and corporate disclosures. AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreCAI MarketRank™: Caris Life Sciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 536th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingCaris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Caris Life Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCaris Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 200.00% in the coming year, from $0.13 to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caris Life Sciences is 69.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Caris Life Sciences is 69.64, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.26.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 12.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.58% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 2.54, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently increased by 1.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.63 News SentimentCaris Life Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for CAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,834,769.00 in company stock.Percentage Held by Insiders50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences (CAI) & The Competition Head-To-Head Contrast1 hour ago | americanbankingnews.comInsider Selling: Caris Life Sciences (NASDAQ:CAI) President Sells $11,883,080.00 in StockSeptember 7 at 4:08 AM | americanbankingnews.comWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax that year in exchange for potential tax-free qualified growth later. Key questions remain: how much to convert, where the tax payment comes from, and whether this years income leaves room. Roth IRAs also avoid lifetime required minimum distributions. A fiduciary financial advisor can help size a conversion around your specific tax situation and goals.September 8 at 1:00 AM | SmartAsset (Ad)Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?September 6 at 9:17 AM | finance.yahoo.comCaris Life Sciences (CAI) Will Present Seven Studies At A Global Lung ConferenceSeptember 5 at 5:18 PM | finance.yahoo.comInsider Selling: Caris Life Sciences (NASDAQ:CAI) President Sells 119,212 SharesSeptember 5 at 6:52 AM | insidertrades.comCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung CancerSeptember 2, 2026 | prnewswire.comCaris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic CancerAugust 27, 2026 | prnewswire.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 at the start of the year. Since then, CAI shares have decreased by 7.1% and is now trading at $25.07. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) released its earnings results on Thursday, February, 26th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.27. Caris Life Sciences's quarterly revenue was up 125.4% compared to the same quarter last year. Read the conference call transcript. Is Caris Life Sciences doing a stock buyback? Caris Life Sciences' board authorized a stock buyback plan on Monday, June 8th 2026, which permits the company to repurchase $100,000,000 in shares, according to EventVestor. This means that the company could buy up to 2.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its stock is undervalued. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an initial public offering on Wednesday, June 18th 2025. The company issued 23,529,412 shares at $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Caris Life Sciences' top institutional shareholders include Braidwell LP (2.92%), PointState Capital LP (2.42%), BlackRock Inc. (1.96%) and California State Teachers Retirement System (1.15%). Insiders that own company stock include David Baxley Spetzler, Jon Halbert, Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today9/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 4 weeks, CAI's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CAI CIK2019410 Webwww.carislifesciences.com Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$26.33 High Price Target$33.00 Low Price Target$21.00 Potential Upside/Downside+5.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E Ratio69.64 Forward P/E Ratio192.85 P/E GrowthN/ANet Income-$68.09 million Net Margins10.62% Pretax Margin10.61% Return on Equity18.77% Return on Assets9.34% Debt Debt-to-Equity Ratio0.66 Current Ratio5.53 Quick Ratio4.88 Sales & Book Value Annual Sales$812.03 million Price / Sales8.72 Cash Flow$1.59 per share Price / Cash Flow15.73 Book Value$2.05 per share Price / Book12.23Miscellaneous Outstanding Shares282,600,000Free Float141,298,000Market Cap$7.08 billion OptionableN/A Beta1.10 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CAI) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredBuffett’s “Green New Deal” (trigger warning!)Warren Buffett's largest stock bet ever now tops 29 billion dollars, dwarfing his historic positions in Coca-C...Porter & Company | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAI Stock Alerts